# Critical Evaluation of LRRK2 Hypotheses
## Overview
The core question—whether G2019S increases signal amplification during lysosomal swelling versus merely elevating the baseline activity floor—requires distinguishing between these mechanistically distinct possibilities. Most hypotheses conflate these, and none provide decisive evidence for either model.
---
## Hypothesis 1: Lysosomal Volume-Sensing Amplifier via RAB29
### Weak Links
- **Recruitment enhancement not demonstrated**: The cited PMIDs establish that RAB29 recruits LRRK2 to stressed lysosomes, but do not show G2019S specifically *enhances* this recruitment relative to WT. This is a critical assumption.
- **Positive feedback loop asserted, not shown**: The paper claims a "pathogenic positive feedback loop" but provides no mechanism for how elevated RAB10-p feeds back to increase RAB29-mediated recruitment.
- **Confuses amplification with ceiling effect**: The proposed experiment measures peak amplitude and rise slope, but a higher ceiling could produce identical kinetics—it would just start from a higher point.
### Counter-Evidence
- If G2019S specifically amplifies RAB29-dependent signals, one would predict RAB29 knockout should specifically normalize the stress response. This prediction is not tested in this hypothesis.
- Multiple studies suggest G2019S increases *overall* LRRK2 activity rather than selectively enhancing localized signals.
### Falsifying Experiment
Perform the live-cell imaging experiment as proposed. **If G2019S and WT show identical rise slope but differ only in baseline offset, this hypothesis is falsified.** The data would support a floor-elevation model, not amplification.
### Revised Confidence: 0.61
The mechanistic claim (enhanced RAB29 recruitment) lacks direct evidence and the experiment as designed cannot distinguish amplification from baseline elevation without careful kinetic analysis.
---
## Hypothesis 2: Dual-Mechanism Model
### Weak Links
- **Two-mechanism hypotheses are disfavored**: This model invokes two separable changes—baseline elevation and membrane affinity—without explaining how they are biochemically linked or why they would be pharmacologically separable.
- **Structural evidence doesn't support membrane affinity change**: The cited cryo-EM study (PMID: 31511666) shows the activation segment widens, affecting catalytic function. It does not demonstrate altered membrane-binding affinity.
- **Membrane association mutants may confound**: The proposed polybasic patch mutations could disrupt other protein-protein interactions or structural stability, not merely membrane targeting.
### Counter-Evidence
- If baseline and signal-dependent effects are truly separable pharmacologically, one would predict the existence of selective modulators. No such agents have been reported.
- The structural evidence primarily implicates the kinase domain, not membrane-targeting regions.
### Falsifying Experiment
Test the proposed membrane-association mutants. **If disrupting membrane association equalizes G2019S and WT baseline RAB10-p but does NOT equalize swelling-induced responses, the dual-mechanism model is partially supported.** However, **if baseline remains elevated despite membrane disruption, the model fails**.
### Revised Confidence: 0.52
This hypothesis is unfalsifiable in its current form because it predicts two mechanisms without identifying distinct readouts. Requires more specific structural predictions.
---
## Hypothesis 3: Therapeutic Window via Amplification Dependence
### Weak Links
- **Assumes stress-dependent pathology**: "Age-dependent neurodegeneration" does not equate to "stress-dependent neurodegeneration." The cited study (PMID: 31694915) shows age-dependent phenotypes but does not demonstrate these require acute stress events.
- **Knockout mice are misleading**: LRRK2 knockout viability is frequently invoked but is confounded by compensatory upregulation of LRRK2-like kinase (LRRK1) in knockout animals.
- **Dose-response interpretation is ambiguous**: Sub-maximal inhibitor efficacy could reflect partial inhibition of *both* baseline and amplified signals, not selective normalization of amplification.
### Counter-Evidence
- The therapeutic window model predicts that preserving baseline function should be safe. However, LRRK2 inhibitors in clinical trials show safety signals that suggest complete kinase inhibition may be tolerated, undermining the "necessary baseline" argument.
- If amplification drives pathology, complete inhibition should be the goal, not partial inhibition.
### Falsifying Experiment
Test whether partial inhibition (sufficient to normalize stress response) actually protects against neurodegeneration in G2019S knock-in mice under stress. **If protection requires near-complete inhibition (i.e., both baseline and amplified signals suppressed), this hypothesis is undermined.** Alternatively, demonstrate that selective normalization of stress responses without affecting baseline prevents pathology.
### Revised Confidence: 0.68
This is the most therapeutically relevant hypothesis but relies on the unproven assumption that amplification is pathogenic. The therapeutic logic is sound, but the mechanistic premise remains uncertain.
---
## Hypothesis 4: RAB29 as Critical Molecular Switch
### Weak Links
- **Zebrafish data may not translate**: The RAB29 knockout rescue in zebrafish (PMID: 31743699) demonstrates developmental compensation rather than neuronal homeostasis. Zebrafish development may be uniquely sensitive to LRRK2 pathway modulation.
- **Specificity of switch function unclear**: RAB29 could modulate overall LRRK2 activity rather than specifically gating amplification. The proposed experiment cannot distinguish these.
- **RAB29 mutations as evidence is circular**: RAB29 PARK23 mutations causing early-onset Parkinsonism show RAB29 is important, but this doesn't establish RAB29 specifically gates amplification.
### Counter-Evidence
- If RAB29 is the critical switch, why do RAB29 mutations cause disease through LRRK2 *activation*? The disease phenotype suggests RAB29 normally suppresses LRRK2 activity, not activates it.
- RAB29 knockout in mammalian neurons has not been shown to normalize G2019S stress responses.
### Falsifying Experiment
Perform the proposed RAB29 knockout in iPSC-derived neurons. **If RAB29 knockout equalizes G2019S and WT swelling responses, this supports the hypothesis.** However, **if G2019S neurons retain elevated RAB10-p even in the absence of RAB29, the "switch" model fails**—suggesting G2019S acts through RAB29-independent pathways.
### Revised Confidence: 0.63
This is a reasonable candidate but the zebrafish-to-mammalian translation is a significant weakness. The experiment is technically feasible and could be decisive.
---
## Hypothesis 5: Membrane Microdomain Partitioning
### Weak Links
- **G2019S is in the kinase domain**: The mutation (G2019S) is located in the kinase activation segment. Membrane partitioning is governed by N-terminal domains (ANK, COR, WD40). There's no structural mechanism proposed for how a kinase domain mutation alters membrane affinity.
- **S1292 evidence is indirect**: Increased S1292 autophosphorylation is a marker of membrane-associated LRRK2, but it does not demonstrate G2019S specifically alters membrane partitioning versus catalytic efficiency.
- **PI4P correlation doesn't prove mechanism**: The studies show PI4P increases during lysosomal swelling and LRRK2 requires PI4P, but this doesn't establish G2019S has altered PI4P sensitivity.
### Counter-Evidence
- Structural studies of G2019S consistently show effects on kinase catalytic loop dynamics, not on membrane-binding interfaces.
- If membrane partitioning were the primary mechanism, one would predict G2019S effects would be cell-type or membrane-composition dependent. No such specificity is observed.
### Falsifying Experiment
Use dSTORM to quantify G2019S vs. WT LRRK2 membrane density. **If G2019S shows identical membrane density under both basal and swollen conditions but elevated RAB10-p, membrane partitioning is falsified.** The prediction is that density correlates with signal, but the hypothesis must show G2019S has *higher* density.
### Revised Confidence: 0.48
The mechanistic link between a kinase domain mutation and membrane targeting is unexplained. This is the weakest of the mechanistic hypotheses.
---
## Hypothesis 6: Baseline Elevation from ER Stress (Epiphenomenon)
### Weak Links
- **PERK activation paradox**: The cited evidence (PMID: 28666988) states that PERK activation causes LRRK2 S935 dephosphorylation. Dephosphorylation at S935 is typically associated with *decreased* kinase activity and membrane association. This would predict *lower* RAB10 phosphorylation, not elevated baseline.
- **Specificity problem**: ER stress is a non-specific perturbation that would elevate LRRK2 activity in WT neurons as well. Why would G2019S specifically show elevated baseline under ER stress?
- **No direct link to RAB10**: The ER stress-PERK pathway is connected to LRRK2 S935, but not to RAB10 phosphorylation, which is the direct substrate of interest.
### Counter-Evidence
- Elevated RAB10-p in G2019S neurons is observed under standard culture conditions, not only under ER stress.
- ER stress is a secondary consequence of many manipulations and may not reflect the primary pathogenic mechanism.
- The hypothesis does not explain why baseline elevation would be specifically tied to G2019S pathology.
### Falsifying Experiment
Perform the PERK inhibitor experiment exactly as proposed. **If GSK2606414 reduces G2019S baseline RAB10-p to WT levels, this hypothesis is supported.** **If G2019S baseline remains elevated despite PERK inhibition, this hypothesis fails.** Importantly, if PERK inhibition reduces baseline in both genotypes, this would suggest baseline elevation is not G2019S-specific.
### Revised Confidence: 0.55
The mechanistic link between PERK and RAB10 phosphorylation is weak, and the hypothesis doesn't explain G2019S specificity. The proposed experiment is straightforward and could be falsifying.
---
## Hypothesis 7: Uncoupling RAB29-Dependent Spatial Control
### Weak Links
- **RAB29 binding interface is poorly characterized**: The cited cryo-EM structure (PMID: 34519112) identifies the binding interface but does not definitively show that G2019S preserves normal affinity. Surface mutations near the interface could allosterically affect binding.
- **The R1078Q mutation may have confounding effects**: R1078 is not in the documented RAB29-binding interface. This mutation could alter kinase activity directly rather than specifically disrupting spatial control.
- **Ectopic activity model lacks direct evidence**: The hypothesis assumes diffuse RAB10 phosphorylation disrupts endosomal trafficking, but this has not been demonstrated in G2019S neurons specifically.
### Counter-Evidence
- The cited evidence that "RAB29 overexpression rescues G2019S phenotypes" (PMID: 30635564) suggests spatial control is not completely uncoupled—if it were, excess RAB29 would not rescue.
- If G2019S truly creates cytosolic/untargeted kinase activity, one would predict elevated RAB10-p in cytosol, not specifically at lysosomes. This has not been shown.
### Falsifying Experiment
Test the engineered R1078Q mutant